Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Duane Veale"'
Autor:
Renato Skerlj, Tuya Ba, Ernest J. McEachern, Elyse Bourque, Ian Baird, Dominique Schols, Wilson Trevor R, Renee Mosi, Jonathan Langille, Yuanxi Zhou, Bryon Carpenter, Michael Bey, Simon P. Fricker, Dana Huskens, Duane Veale, Rebecca S.Y. Wong, Gary Bridger, Curtis Harwig, Veronique Bodart, Ron MacFarland, Markus Metz, Sanjay Danthi
Publikováno v:
ACS Medicinal Chemistry Letters. 3:216-221
A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing lipophilicity wa
Autor:
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Jonathan Langille, Curtis Harwig, Duane Veale, Wen Yang, Tongshong Li, Yongbao Zhu, Michael Bey, Ian Baird, Michael Sartori, Markus Metz, Renee Mosi, Kim Nelson, Veronique Bodart, Rebecca Wong, Simon Fricker, Ron Mac Farland, Dana Huskens, Dominique Schols
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:6950-6954
A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of
Autor:
Curtis Harwig, Rossana Wauthy, Renato Skerlj, Fluri Maria Di, Yongbao Zhu, Duane Veale, Dominique Schols, Gary Bridger, Helen Yee, Wen Yang, Wilson Trevor R, David Bogucki, Christopher Ronald Smith, Erik De Clercq, Krystyna A. Skupinska, Jonathon Langille, Jason M. Crawford, Dana Huskens, Ernie Mceachern
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:262-266
An early lead from the AMD070 program was optimized and a structure-activity relationship was developed for a novel series of heterocyclic containing compounds. Potent CXCR4 antagonists were identified based on anti-HIV-1 activity and Ca(2+) flux inh
Publikováno v:
Canadian Journal of Chemistry. 82:240-253
The photochemistry of naphthols 1, 2, 4, 5 and 9, and phenol 10 has been studied in aqueous solution with the primary aim of exploring the viability of such compounds for naphthoquinone and quinone methide photogeneration, along the lines already dem
Autor:
Curtis Harwig, Dominique Schols, Gang Chen, Wen Yang, Duane Veale, Susan Nan, Simon P. Fricker, Alan Kaller, Danielle Guay, Jason M. Crawford, Michael Satori, Markus Metz, Yongbao Zhu, Helen Yee, Maria Krumpak, Elyse Bourque, Wilson Trevor R, David Bogucki, Bryon Carpenter, Michael Bey, David C. Leitch, Ron MacFarland, David Gauthier, Ian Baird, Rebecca Wong, Renato T. Skerlj, Jonathan Langille, Yuanxi Zhou, Gary Bridger, Renee Mosi, Ernest J. McEachern, Tuya Ba, Tong-Shuang Li, Krystyna Vocadlo, Veronique Bodart
Publikováno v:
Journal of medicinal chemistry. 56(20)
The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidi
Autor:
Dana Huskens, Ernest J. McEachern, Yongbao Zhu, Helen Yee, Krystyna A. Skupinska, Michael Sartori, Alan Kaller, Gary Bridger, Renato Skerlj, Erik De Clercq, Duane Veale, Ian Baird, Letian Wang, Kate Burrage, Dominique Schols, Wen Yang, Christopher Ronald Smith, Curtis Harwig, Rossana Wauthy
Publikováno v:
Bioorganicmedicinal chemistry letters. 21(5)
A novel series of CXCR4 antagonists were identified based on the substantial redesign of AMD070. These compounds possessed potent anti-HIV-1 activity and showed excellent pharmacokinetics in rat and dog.
Autor:
Duane Veale, Jason B. Crawford, Gary Bridger, Erik De Clercq, Dominique Schols, Ernest J. McEachern, Bem Atsma, Katrien Princen, Jonathon Langille, Renato Skerlj, Yuanxi Zhou, Al Kaller, Curtis Harwig, Sigrid Hatse, Susan Nan, Wilson Trevor R
Publikováno v:
Journal of medicinal chemistry. 53(8)
The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR